Table 2.
Overview of the eligible studies subsequently excluded from the present review.
| Reference | Year | Study type | Patients type | Patients who completed the study (n) |
|---|---|---|---|---|
| Pirola et al. (26) | 2014 | Prospective | Hypothyroid patients, treated with tablet levothyroxine (LT4), undergone bariatric surgery | 4 |
| Giusti et al. (21) | 2014 | Prospective | Thyroidectomized for differentiated thyroid cancer | 54 |
| Fallahi et al. (27) | 2016 | Prospective | Patients with optimal TSH values during tablet T4 treatment | 141 |
| Fallahi et al. (28) | 2016 | Prospective | Patients with autoimmune atrophic gastritis | 5 |
| Fallahi et al. (29) | 2017 | Prospective | Patients with lactose intolerance | 5 |
| Peirce et al. (30) | 2017 | Prospective | Thyroidectomized patients | 3 |
| Hommel and Delgrange (31) | 2017 | Prospective | Hypothyroid patient, treated with tablet LT4, undergone bariatric surgery | 1 |
Articles appear in the table by the year of publication. All studies switched patients from tablet to liquid LT4 at unchanged dose. These studies were excluded from our analysis according to the studies selection criteria (see Materials and Methods).